India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election 
Thailand Inflation Remains Negative for 10th Straight Month in January 
Dollar Steadies Ahead of ECB and BoE Decisions as Markets Turn Risk-Off 
Instagram Outage Disrupts Thousands of U.S. Users 
Mizuho has unveiled its January US Top Picks, spotlighting Chewy, GE Vernova, Enliven Therapeutics, Quest Diagnostics, DuPont, and Salesforce. These companies align with Mizuho’s high-conviction investment ideas, driven by expected catalysts over the next year.
Chewy earned a spot for its strong EBITDA margin expansion, supported by automation, vet-focused initiatives, and app engagement. With a $42 price target, analysts see a 17% upside for the pet retailer.
GE Vernova stands out as a key player in power generation, providing turbines and grid equipment that supply 30% of global electricity. Mizuho forecasts significant growth in natural gas power contracts by 2025, driven by rising data center demand.
Enliven Therapeutics shows promise with ELVN-001, an investigational tyrosine kinase inhibitor (TKI) demonstrating early efficacy in chronic myeloid leukemia (CML). Analysts see potential for ELVN-001 to expand into first-line treatment, bolstering its market outlook.
Quest Diagnostics appeals for its stable cash flow and growth opportunities in diagnostics, underpinned by Medicare and commercial pricing strength. Mizuho highlights its acquisition pipeline and EPS growth forecast for 2025.
DuPont’s planned split into ElectronicsCo, WaterCo, and the new DuPont is seen as a value catalyst. Analysts cite the company’s leadership in specialty materials like Kevlar and Tyvek, alongside seasonal sales recovery and electronics growth.
Salesforce rounds out the list, with Data Cloud and Agentforce technology driving productivity and revenue growth. Upcoming updates, multi-cloud deals, and margin improvements position Salesforce for continued success in digital transformation.
These additions reflect Mizuho’s strategic outlook for 2024, showcasing diverse opportunities across industries.
